Have Two Close Friends? Statistically, One of the Three of You Has MASLD
Why metabolic liver disease affects roughly 34% to 38% of U.S. adults — and why Type 2 diabetes, prediabetes, belly fat, and normal-looking blood tests hide millions of cases.
People still assume liver disease belongs almost exclusively to heavy drinkers or viral hepatitis. That assumption is decades out of date. Today, MASLD is the most common chronic liver condition on earth, affecting roughly a hundred million Americans — and most of them feel completely fine while walking around with it.
If you live with Type 2 diabetes, prediabetes, polycystic ovary syndrome (PCOS), sleep apnea, high triglycerides, or extra weight around your midsection, your liver deserves a real stiffness check — not a guess based on whether you look healthy from across the exam room.
Highest-Priority Groups for Proactive Screening
- Type 2 Diabetes: Roughly 65% have MASLD, and 15%–20% already have clinically meaningful fibrosis (F2–F4).
- Abdominal / Visceral Adiposity: BMI ≥25 (≥23 in Asian adults) or waist >37 in. (men) / >31.5 in. (women) with metabolic traits.
- Persistently Elevated ALT or AST for more than 6 months, or steatosis spotted incidentally on any abdominal scan.
- First-Degree Family History of MASH cirrhosis or liver cancer — family risk runs strong and warrants early elastography.
Associated Conditions Doctors Should Check
- Obstructive Sleep Apnea (OSA): Nighttime oxygen drops accelerate liver inflammation and fibrosis.
- Polycystic Ovary Syndrome (PCOS) & Hypothyroidism: Both raise insulin resistance and MASH risk.
- Psoriasis & Chronic Kidney Disease: Share systemic inflammatory pathways with MASH.
- Hispanic / Latino & Asian Populations: Higher prevalence of the PNPLA3 genetic variant increases MASH susceptibility even at lower body weights.

All 5 Adult Cardiometabolic Criteria — Exact U.S. & Asian Thresholds
Under the global MASLD definition, doctors pair evidence of liver steatosis (≥5% fat on imaging or biopsy) with five everyday cardiometabolic markers you probably already have sitting in your electronic chart. Meeting just one of these five thresholds (in the absence of heavy alcohol intake or rarer liver diseases) confirms that metabolic overload is driving your liver fat. Notice how Asian adults reach visceral fat spillover at lower body weights, which is why international guidelines use ethnicity-adjusted BMI and waist cutoffs:
| Cardiometabolic Criterion | Standard Adult Threshold | Asian Adult Threshold | What It Signals Inside the Liver |
|---|---|---|---|
| 1. Overweight or Central Waist Adiposity | BMI ≥25.0 kg/m2 OR waist circumference >94 cm (37.0 in.) in men / >80 cm (31.5 in.) in women | BMI ≥23.0 kg/m2 OR waist >90 cm (35.4 in.) in men / >80 cm (31.5 in.) in women | Visceral fat packed around abdominal organs drains free fatty acids straight into the portal vein feeding the liver. |
| 2. Elevated Glucose, Prediabetes, or Type 2 Diabetes | Fasting glucose ≥100 mg/dL (5.6 mmol/L), 2-hr post-load glucose ≥140 mg/dL, HbA1c ≥5.7%, diagnosed Type 2 diabetes, or active glucose-lowering medication | High insulin switches on hepatic de novo lipogenesis (brewing new fat from sugar) while failing to brake fat-cell leakage. | |
| 3. Elevated Blood Pressure | Blood pressure ≥130/85 mmHg OR taking any prescribed blood-pressure medication | Reflects systemic vascular stiffness, sympathetic nervous system activation, and endothelial insulin resistance. | |
| 4. Elevated Plasma Triglycerides | Fasting triglycerides ≥150 mg/dL (1.70 mmol/L) OR taking lipid-lowering therapy | Shows the liver is working overtime exporting excess fat droplets packaged inside VLDL particles. | |
| 5. Low HDL Cholesterol | Plasma HDL-C ≤40 mg/dL (1.0 mmol/L) in men OR ≤50 mg/dL (1.3 mmol/L) in women, OR lipid-lowering treatment | Classic twin of high triglycerides in atherogenic dyslipidemia — raising both coronary plaque and MASH risk. | |

Why Type 2 Diabetes Carries ~65% MASLD & ~15%–20% Fibrosis Risk
If I could hang one poster in every diabetes clinic in America, it would say this: Type 2 diabetes and MASH are two chapters of the exact same metabolic book. Across global elastography and biopsy cohorts (Younossi et al., 2023), roughly 65% to 70% of adults living with Type 2 diabetes have MASLD, about one-third have active MASH, and 15% to 20% already carry clinically meaningful F2–F4 liver fibrosis — most without a single symptom and half with normal ALT.
Why is the overlap so steep? In Type 2 diabetes, insulin-resistant fat tissue leaks fatty acids around the clock while the pancreas pumps out extra insulin trying to wrestle blood sugar down. Inside the liver, insulin resistance is strangely selective: hepatocytes stop responding to insulin's command to turn off glucose output, yet they keep obeying insulin's command to manufacture fat! Recognizing this hidden epidemic, the American Diabetes Association (ADA) 2025 and 2026 Standards of Care recommend universal fibrosis screening with FIB-4 for adults with Type 2 diabetes or prediabetes (especially when paired with overweight/obesity or cardiometabolic traits), followed by elastography whenever FIB-4 is ≥1.3 (see our ADA Screening Summary).
Endocrine, Sleep & Systemic Amplifiers That Accelerate MASH
Metabolic risk doesn't stop at blood sugar and waist size. Several common hormone, sleep, and inflammatory conditions quietly pour fuel on liver scarring — and treating them often helps your liver calm down faster:
- Obstructive Sleep Apnea (OSA): Repeated nighttime oxygen drops (chronic intermittent hypoxia) trigger hypoxia-inducible factors (HIF-1α and HIF-2α), surges of stress hormones, and oxidative injury inside liver Zone 3. Biopsy studies show untreated OSA independently raises MASH and fibrosis severity even after adjusting for BMI.
- Polycystic Ovary Syndrome (PCOS): Elevated androgens (such as free testosterone) combined with deep skeletal-muscle insulin resistance double to triple MASLD prevalence in younger women, often decades before anyone thinks to check a liver scan.
- Hypothyroidism (Underactive Thyroid) & Pituitary Deficiency: Thyroid hormone drives mitochondrial fat burning inside hepatocytes via the THR-β receptor — in fact, mimicking that exact liver thyroid pathway is how FDA-approved Rezdiffra works. Even mild untreated hypothyroidism raises MASH risk and cholesterol.
- Psoriasis & Chronic Kidney Disease (CKD): Psoriasis shares systemic IL-17 and TNF-α inflammatory pathways with MASH (and requires careful fibrosis monitoring if methotrexate is ever discussed), while MASLD and CKD reinforce each other through microvascular and uremic stress.
Inherited Genetic Modifiers: Why Family History Runs Deep
Patients often ask me why their brother-in-law can eat fast food every day at 280 pounds with a spotless liver while they developed F3 MASH at 165 pounds. Part of the answer sits in four well-mapped liver genes (explore Genetics & Family Risk):
- PNPLA3 (I148M variant): The strongest common genetic driver of MASLD, MASH, cirrhosis, and hepatocellular carcinoma worldwide. The I148M change gums up an enzyme on the surface of lipid droplets inside hepatocytes and directly provokes hepatic stellate cells to spin more scar tissue. It occurs most frequently in Hispanic/Latino populations (~45%–50% allele frequency), moderately in Asian and European populations (~20%–35%), and less often in Black populations — helping explain real-world differences in MASH rates at identical BMIs.
- TM6SF2 (E167K variant): Impairs the liver's ability to load triglycerides onto VLDL particles for export. Ironically, carriers often have pleasingly low blood LDL cholesterol while trapping excess fat and fibrosis risk inside their liver.
- MBOAT7 (rs641738): Alters cell-membrane phospholipid remodeling, nudging excess arachidonic acid into inflammatory pathways inside liver tissue.
- HSD17B13 (Protective loss-of-function variant): Nature's encouraging counterbalance! People born with an inactive copy of HSD17B13 still accumulate liver fat if insulin resistant, yet experience 30% to 50% lower rates of MASH inflammation and cirrhosis — a discovery now inspiring targeted RNA-interference drugs in our Emerging MASH Drug Pipeline.
- The 'normal ALT' trap: Many primary care clinics only investigate the liver when ALT or AST turn red on a lab report — yet up to 50% of patients with MASLD (and many with bridging fibrosis) have enzymes inside the lab's 'normal' reference range.
- Incidental scan notes brushed aside: Phrases like 'mild hepatic steatosis' on an ER CT scan or gallbladder ultrasound are often treated as harmless background noise rather than a cue to stage fibrosis.
- What you can do today: Open your patient portal, grab your most recent AST, ALT, and Platelet Count, and check your own FIB-4 score in 30 seconds.
Common Questions Patients & Families Ask
Why are BMI and waist screening cutoffs lower for Asian adults?
Across South Asian, East Asian, and Southeast Asian populations, subcutaneous fat storage fills up earlier, so excess energy spills into deep visceral abdominal fat and liver cells at lower body weights. A BMI of 23.5 kg/m2 in an Asian adult carries roughly the same visceral insulin resistance and MASLD risk as a BMI of 25 to 27 kg/m2 in European-ancestry cohorts, which is why international guidelines adjust the threshold to BMI ≥23.
Does Type 1 diabetes carry the same 65% MASLD risk as Type 2 diabetes?
No. Uncomplicated Type 1 diabetes is an autoimmune insulin-deficiency condition rather than primary insulin resistance, so baseline MASLD rates sit closer to the general population (~15%–20%). However, if someone with Type 1 diabetes also develops central weight gain, high triglycerides, or 'double diabetes' insulin resistance, their MASLD and fibrosis risk climbs and warrants FIB-4 checks.
Should I pay out of pocket for a commercial genetic test for PNPLA3 or HSD17B13?
Right now, clinical societies do not recommend routine out-of-pocket genetic testing for most patients, because knowing your PNPLA3 status doesn't yet change which approved diet or medication you receive — whereas FibroScan and FIB-4 directly measure your actual liver tissue today. That will likely shift over the next few years as targeted PNPLA3 and HSD17B13 RNA therapies advance through clinical trials.
If my parent or sibling had MASH cirrhosis, is a FIB-4 blood score enough for me?
No — don't stop at FIB-4 alone if a first-degree relative had MASH cirrhosis or liver cancer. Because FIB-4 can under-detect early fibrosis in adults under age 45, AASLD and AGA guidance recommend going straight to a direct imaging or blood fibrosis test (such as FibroScan / SWE elastography or an ELF test) for first-degree relatives of patients with advanced MASH cirrhosis.
Can treating my sleep apnea with CPAP actually help my liver?
Yes. Untreated obstructive sleep apnea subjects your liver's oxygen-sensitive Zone 3 cells to dozens of mini-hypoxia surges every night, driving oxidative stress, insulin resistance, and stellate-cell activation. Consistent CPAP therapy (alongside weight/GLP-1 sleep apnea care) improves daytime fatigue, lowers blood pressure, and removes a major nighttime accelerator of MASH.
Where to Go Deeper: Related Guides & Trusted Resources
How the American Diabetes Association recommends universal FIB-4 fibrosis checks for adults with Type 2 diabetes or prediabetes.
Explore how inherited lipid-droplet variants shape liver inflammation and when relatives need direct elastography.
Check whether your routine AST, ALT, and Platelet numbers point toward low risk or warrant a stiffness scan.
Official American Diabetes Association clinical practice standards covering cardiometabolic and MASH co-management.
Evidence-based risk-stratification guidelines from the American Association for the Study of Liver Diseases.